Vita Coco Company, Inc. SEC Filings

Insider transactions by Vita Coco Company, Inc. (COCO) show the chief operating officer engaged in a planned sale of 3,173 shares of common stock under a Rule 10b5-1 trading plan at $42.50 per share, which reduced his direct holdings from 79,300 to 76,127 shares. The filing also reports the grant and continued ownership of multiple non-qualified stock options with exercise prices ranging from $10.178 to $33.36, some fully vested and exercisable and others subject to multi-year vesting schedules. The disclosure records routine option grants and an executed plan-based sale, providing transparency about executive equity and compensation.

Verlinvest Beverages SA reported beneficial ownership of 4,097,161 shares of The Vita Coco Company, Inc. (ticker COCO), representing 7.2% of the company's outstanding common stock based on 56,822,981 shares outstanding as of July 28, 2025. The filing is a Schedule 13G/A under the Securities Exchange Act and shows Verlinvest holds sole voting and dispositive power over all reported shares. The report lists Verlinvest's address in Ixelles, Belgium, and cites the issuer's principal executive office in New York. No shared ownership, group affiliations, or parties on whose behalf shares are held are disclosed.

Insider sales by Vita Coco CEO and related trusts. Martin Roper reported multiple Rule 10b5-1 sales of common stock on September 24-25, 2025, disposing of blocks of 5,000 and 400 shares at weighted average prices in the ~$40.00–$41.67 range. After these transactions the reporting person directly held 319,297 shares. Related family trusts and spouses show indirect holdings ranging from 252,515 to 253,931 shares, and an additional 61,200 shares are held by a spouse. The filing also discloses large outstanding stock option positions fully exercisable or vesting across 2022–2026, totaling several hundred thousand underlying shares.

Martin Roper, CEO and Director of Vita Coco Company, Inc. (COCO), reported open-market sales of common stock executed under a Rule 10b5-1 trading plan on September 22 and 23, 2025. The filing shows two sales by the reporting person of 5,000 shares on 09/22/2025 and 5,000 shares on 09/23/2025 at weighted-average prices in the ~$40.14–$40.52 range, leaving 324,297 shares held directly after the 09/23 sale. The form also discloses multiple indirect holdings through family trusts and a spouse, and a total of 1,099,460 outstanding stock options across several grant dates and exercise prices, including fully vested options exercisable now.

Michael Kirban, Executive Chairman and Director of Vita Coco Company, Inc. (COCO), reported transactions on 09/22/2025. He sold 20,000 shares of common stock pursuant to a Rule 10b5-1 trading plan at a weighted average price of $41.535 per share. The Form 4 shows he beneficially owns 1,529,049 shares indirectly through the Michael Kirban 2010 Trust and additional holdings reflected as direct and indirect positions. The filing also lists multiple outstanding non-qualified stock options with exercise prices from $10.178 to $32.78 and varying vesting or exercisability dates.

Martin Roper, a director and CEO of Vita Coco Company, Inc. (COCO), amended a Form 4 to report multiple sales of common stock executed pursuant to a Rule 10b5-1 trading plan on September 15–17, 2025. The Form 4/A shows a series of disposals reported as sales (code S) that reduced both direct and indirect beneficial holdings and reports weighted-average prices for the transactions in ranges approximately between $40.00 and $40.54 per share. The filing also discloses several fully vested and unvested non‑qualified stock options exercisable for large blocks of common stock, with exercise prices from $10.178 to $32.78 and various vesting schedules and expiration dates through 2035. The amendment restates the original Form 4 filed September 18, 2025.

Vita Coco insider Form 4: Martin Roper stock sales and option holdings. The filing reports that Martin Roper, CEO and director, sold four blocks of common stock on 09/18/2025 pursuant to a Rule 10b5-1 trading plan, disposing of 5,000 shares in his name and 5,000 shares each tied to three family trusts for a total reported disposals of 20,000 shares at weighted average prices around $40.00–$40.11 per share. The filing also discloses substantial currently exercisable and non-exercisable non-qualified stock options totaling 1,098,460 underlying shares across multiple grants with exercise prices ranging from $10.178 to $32.78.

Charles van Es, Chief Sales Officer of Vita Coco Company, Inc. (COCO), reported multiple transactions on 09/17/2025 under a Rule 10b5-1 plan. He purchased 20,000 shares via option exercises at a stated exercise price of $10.178 per share (reported as two non-qualified option exercises of 10,000 shares each) and sold 20,000 shares in Rule 10b5-1 plan transactions at a weighted average price of $42.04 per share (sales occurred across prices ranging from $42.00 to $42.19 and $42.00 to $42.18 as disclosed). Following the reported non-derivative transactions, his direct beneficial ownership figures listed are 94,328 shares and 84,328 shares on the lines reported.

Table II shows multiple outstanding non-qualified stock options at various exercise prices and vesting schedules, including currently exercisable options and several tranches that vest over future years, totaling significant option-based potential ownership.

Kenneth Sadowsky, a director of Vita Coco Company, Inc., sold 3,900 shares of common stock on 09/17/2025 under a Rule 10b5-1 trading plan at a weighted average price of $40.034 (individual trade prices ranged from $39.65 to $40.22). After the sale he beneficially owned 623,866 shares. The filing also discloses a fully vested, currently exercisable non-qualified stock option covering 27,300 underlying shares with a $10.178 exercise price. The Form 4 was filed by an attorney-in-fact on behalf of the reporting person and identifies the sale as pre-arranged under Rule 10b5-1.